ArticleRadiation oncology (London, England)2026
The regional-control of prophylactic irradiation dose reduction of level Va in nasopharyngeal carcinoma (NPC).
Article in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe regional-control of prophylactic irradiation dose reduction of level Va in NPC has not been reported in detailed. We separately evaluated the metastatic nodes of the two sides of each patient’s neck and aim to assess the regional-control based on the irradiation dose reduction of level Va. METHODS AND MATERIALS: We evaluated the regional-control data of 51 NPC patients with 102 neck sides (NS) in our institution from 2020 to 2025. All patients received intensity-modulated radiation therapy (IMRT) ± chemotherapy. The clinical target volume (CTV2) was defined as intermediate risk nodal regions including the ipsilateral level II and III in the NS without nodal spread or with isolated metastases in level VII. CTV3 was defined as low-risk nodal region only including the unilateral or bilateral level Va, and each NS of CTV3 was individually delineated. All patients received IMRT in 30–33 fractions. The Kaplan-Meier method was used to calculate the survival rate, including overall survival (OS), progression-free survival (PFS), local recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS). The equivalent dose in 2 Gy per fraction (EQD2) was calculated according to the formula: EQD2 = d*n((α/β + d)/(α/β + 2d)).
resultsThe number of patients with N0, N1, and N3 stage is 8 (15.7%), 40 (78.4%), and 3 (5.9%), respectively, the 5- year OS, PFS, LRFS, and DMFS were 87.8%, 79.8%, 97.8%, and 85.5%, respectively. There are 63 CTV3 received prophylactic irradiation dose reduction in level Va (12 patients in the bilateral NS, 39 patients in the unilateral NS). There are 5 PTV3 received prophylactic irradiation dose of 25–34 Gy (EQD2), 7 PTV3 received 48 Gy (EQD2), and 51 PTV3 received 50–51.04 Gy (EQD2), and no patient presented local failure in CTV3.
conclusionsThe prophylactic irradiation dose of level Va can be reduced or even omitted in NPC patients with N0 stage, N1 and N3 stage with or without isolated metastases in the unilateral/bilateral level VII.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.